INTRAARTERIAL HEPATIC CARBOPLATIN-BASED CHEMOTHERAPY FOR OCULAR MELANOMA METASTATIC TO THE LIVER - REPORT OF A PHASE-II STUDY
INTRAARTERIAL HEPATIC CARBOPLATIN-BASED CHEMOTHERAPY FOR OCULAR MELANOMA METASTATIC TO THE LIVER - REPORT OF A PHASE-II STUDY
复制标题
DOI：
10.1177/030089169408000107
复制
发表时间：
1994-02-28
期刊：
影响因子：
--
通讯作者：
SMERIERI, F
中科院分区：
文献类型：
--
作者：
CANTORE, M;FIORENTINI, G;SMERIERI, F
目的和背景：眼部黑色素瘤倾向于转移到肝脏，在很长一段时间内不会转移到生物体的其他部位。因此，应特别指出区域性治疗。方法：8例眼部转移性黑色素瘤患者在门诊接受以卡铂为基础的肝动脉化疗，300 mg/m2，每2周1次。所有患者均接受剖腹手术，并通过胃十二指肠动脉植入动脉插管装置。结果：总有效率为38%，中位生存期为15个月。该方案耐受性良好，主要毒性是骨髓抑制；报告了任何肝和/或胆管损害的情况。结论：卡铂适合于肝动脉化疗，对眼部转移性黑色素瘤疗效较好。
Aims and Background: ocular melanoma tends to metastasize to the liver, sparing for a long time the rest of the organism. Therefore, a regional treatment is especially indicated. Methods: eight patients with ocular melanoma metastatic to the liver were treated with intra-arterial hepatic carboplatin-based chemotherapy at the dose of 300 mg/m2 once every two weeks at an out-patient clinic. All the patients were submitted to laparotomy with surgical implantation of an arterial port device through the gastroduodenal artery. Results: the overall response rate was 38% with a median survival time of 15 months. The regimen was well tolerated and the principle toxicity was myelosuppression; any instance of hepatic and/or cholangitic damage was reported. Conclusions: Carboplatin seems suitable for intra-arterial hepatic chemotherapy and active in ocular melanoma metastic to the liver.